TORONTO, Dec. 11, 2017 /PRNewswire/ — ImmunoBiochem Corporation, a Canadian biopharmaceutical company developing novel biological therapeutics, has completed a new round of financing led by angel investors and the company’s founding investor. ImmunoBiochem has also expanded its operations and is now located at Johnson & Johnson Innovation, JLABS in Toronto (JLABS @ Toronto).
ImmunoBiochem is solving the problem of tumor heterogeneity by targeting a novel class of proteins in the tumor microenvironment with Antibody Drug Conjugates (ADCs) – a promising class of anticancer therapeutics that combine the selectivity of targeted biologics with the potency of highly cytotoxic small-molecule drugs. ImmunoBiochem’s R&D is focused on the cancer cell secretome – the totality of proteins secreted by cancer cells. Select cancer targets are only secreted by cancer cells and accumulate in tumors, and can be exploited for targeted and selective delivery of cytotoxic payloads with ImmunoBiochem’s therapeutics platform. ImmunoBiochem’s highest priority is to transform the life of patients with triple-negative breast cancer (TNBC) – an aggressive disease with poor survival that does not respond to major therapies. Continue reading